公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial | Reich K.; Gooderham M.; Tha?i D.; Crowley J.J.; Ryan C.; Krueger J.G.; TSEN-FANG TSAI ; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C. | The Lancet | 191 | 157 | |
2019 | Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study | Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. | Journal of the American Academy of Dermatology | 15 | 13 | |
2015 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial | Tha?i D.; Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Hugot S.; You R.; Milutinovic M. | Journal of the American Academy of Dermatology | 467 | 418 | |
2017 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1?year: Results from the CLEAR study | Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Hugot S.; You R.; Milutinovic M.; Tha?i D. | Journal of the American Academy of Dermatology | 255 | 227 |